SEC sub­poe­naes Bio­Marin in dris­apersen probe; Job hunt­ing? The FDA has hun­dreds of open po­si­tions

Bio­Marin $BM­RN has more headaches to con­tend with on its Duchenne mus­cu­lar dy­s­tro­phy drug dris­apersen. The com­pa­ny says in its new­ly post­ed quar­ter­ly re­port with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.